Latest Organofluorides Stories
50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months SAN ANTONIO, Sept. 8, 2014 /PRNewswire/ -- GenSpera, Inc.
MarketOptimizer.org adds new report "Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" to its store.
DALLAS, September 7, 2014 /PRNewswire/ -- MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its
Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone.
Pharmacokinetics, Safety and Tolerability of NVR-1221 Support Advancement to Phase 1b Clinical Studies in Patients with Chronic HBV Infection DOYLESTOWN, Pa., Sept.
Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market SAN ANTONIO, Sept.
AUSTIN, Texas, Sept.
The Firm is evaluating potential Lipitor lawsuits on behalf of individuals who allegedly developed Lipitor diabetes injuries after taking the cholesterol-lowering statin drug. New
Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY
- The act of sweetening by admixture of some saccharine substance.